{"entity":{"id":"jm2","kind":"drug","name":"JM2","aka":["Cx43 mimetic peptide"],"tldr":"JM2 is an experimental peptide from Acomhal Research aimed at the stem-like cells that let glioblastoma grow back. It has not yet been tested in people.","summary":"JM2 is the connexin 43 mimetic peptide that Acomhal Research's 2026 National Cancer Institute STTR award describes; the award abstract reports that it reduced glioblastoma stem cell populations in patient-derived models in vivo, and the award funds delivering it by an alphavirus vector. No registered trial was found.","status":"preclinical","asOf":"2026-11-04","links":[{"label":"NIH RePORTER: award 1R41CA306619-01A1","url":"https://reporter.nih.gov/project-details/11409740"},{"label":"Acomhal Research: glioblastoma","url":"https://acomhal.com/glioblastoma/"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["acomhal-research"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"JM2","modality":"Mimetic peptide","mechanism":"A connexin 43 mimetic peptide that, according to the NIH award abstract, disrupts the interaction of Cx43 with microtubules in glioblastoma stem cells and kills them without affecting normal brain cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/jm2/","neighbours":{"company":[{"id":"acomhal-research","kind":"company","name":"Acomhal Research","route":"/companies/acomhal-research/"}]}}